LGALS3 and Alzheimer disease: Genomic association studies confirmed variants of galectin-3 as risk factors for AD (Trompet et al., 2012; Boza-Serrano et al., 2019), and galectin-3 levels in blood or CSF were shown to be elevated in AD patients (Wang X. et al., 2015; Yazar et al., 2021; Boza-Serrano et al., 2022).